Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Cho, EunJu ^a   Kim, Hyo Cheol ^b   Lee, Jeong Hoon ^b   Yoo, Jeong Ju ^b   Choi, Won Mook ^b   Cho, Young Youn ^b   Lee, Min Jong ^b   Cho, Yuri ^b   Lee, Dong Hyeon ^b   Lee, Yun Bin ^b   Yu, Su Jong ^b   Kim, Yoon Jun ^b   Yoon, Jung Hwan ^b   Chung, Jin Wook ^b   Kim, Chung Yong ^b   Lee, Hyo Suk ^b  

^a Kangwon National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADRIMYCIN RDF; ALPHA FETOPROTEIN; DOXORUBICIN; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CHEMOEMBOLIZATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TIME TO PROGRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84897104592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090862     Document Type: Article

References (31)

1. Zhu AX, Duda DG, Sahani DV and Jain RK (2011) HCC and angiogenesis: possible targets and future directions. Nature reviews Clinical oncology 8: 292-301.
2. Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, et al. (2002) Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 20:4459-4465. (Pubitemid 35334758)
3. Llovet JM, Real MI, Montana X, Planas R, Coll S, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739. (Pubitemid 34607087)
4. Bruix J, Sherman M and American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
5. Maki RG (2010) Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 28: 4985-4995.
6. Catrina SB, Botusan IR, Rantanen A, Catrina AI, Pyakurel P, et al. (2006) Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I. Clin Cancer Res 12: 4506-4514. (Pubitemid 44297799)
7. Wu Y, Yakar S, Zhao L, Hennighausen L and LeRoith D (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer research 62: 1030-1035. (Pubitemid 34160283)
8. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566. (Pubitemid 28067285)
9. Key TJ, Appleby PN, Reeves GK and Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. The lancet oncology 11: 530-542.
10. Lorenzo-Zuniga V, Bartoli R, Masnou H, Montoliu S, Morillas RM, et al. (2007) Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 52: 3245-3250. (Pubitemid 47512509)
11. Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, et al. (2008) Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 49: 34-42.
12. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, et al. (2002) Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 95: 2539-2545. (Pubitemid 35424040)
13. Shao YY, Huang CC, Lin SD, Hsu CH and Cheng AL (2012) Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res 18: 3992-3997.
14. Cho EJ, Lee JH, Yoo JJ, Choi WM, Lee MJ, et al. (2013) Serum Insulin-Like Growth Factor-1 Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. Clin Cancer Res.
15. Lencioni R and Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease 30: 52-60.
16. Kim HC, Lee JH, Chung JW, Kang B, Yoon JH, et al. (2013) Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. Journal of vascular and interventional radiology : JVIR 24: 274-283.
17. Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, et al. (2013) Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 58: 1181-1187.
18. Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, et al. (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 24: 965-973.
19. Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, et al. (2013) Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. European journal of cancer 49: 826-834.
20. Heagerty PJ, Lumley T and Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344. (Pubitemid 30422619)
21. Fluss R, Faraggi D and Reiser B (2005) Estimation of the Youden Index and its associated cutoff point. Biometrical journal Biometrische Zeitschrift 47: 458-472. (Pubitemid 41229379)
22. Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, et al. (2012) Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. Journal of gastroenterology 47: 686-695.
23. Poon RT, Lau CP, Cheung ST, Yu WC and Fan ST (2003) Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer research 63: 3121-3126. (Pubitemid 36735862)
24. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, et al. (2011) I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 80: 373-381.
25. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, et al. (2011) Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29: 3892-3899.
26. Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, et al. (1997) Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 113: 1682-1691. (Pubitemid 27461257)
27. Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, et al. (2010) Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 51: 912-921.
28. Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, et al. (2005) Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 43: 630-636. (Pubitemid 41253230)
29. Yang JD, Nakamura I and Roberts LR (2011) The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Seminars in cancer biology 21: 35-43.
30. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. The New England journal of medicine 359: 1995-2004.
31. Poon RT (2009) Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16: 792-794.